Bicycle Therapeutics plc
BCYC
$4.01
-$0.18-4.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -78.46% | -91.11% | 1,193.28% | 338.49% | -68.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.46% | -91.11% | 1,193.28% | 338.49% | -68.81% |
| Cost of Revenue | -42.05% | -18.01% | -4.28% | 24.02% | 77.31% |
| Gross Profit | 40.49% | 2.59% | 104.61% | -4.44% | -121.87% |
| SG&A Expenses | -24.14% | -15.26% | 1.09% | -0.96% | 15.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.35% | -17.23% | -2.57% | 16.18% | 59.84% |
| Operating Income | 37.00% | 6.73% | 69.19% | -2.67% | -85.65% |
| Income Before Tax | 36.55% | 1.92% | 64.32% | -8.56% | -99.47% |
| Income Tax Expenses | 138.96% | 115.82% | 216.91% | 105.95% | -300.87% |
| Earnings from Continuing Operations | 36.25% | -0.12% | 61.13% | -16.33% | -98.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.25% | -0.12% | 61.13% | -16.33% | -98.31% |
| EBIT | 37.00% | 6.73% | 69.19% | -2.67% | -85.65% |
| EBITDA | 37.00% | 6.15% | 70.44% | -3.44% | -88.65% |
| EPS Basic | 36.75% | 0.58% | 61.30% | -15.81% | -48.90% |
| Normalized Basic EPS | 37.04% | 2.61% | 74.02% | -10.00% | -49.75% |
| EPS Diluted | 36.75% | 0.58% | 61.30% | -15.81% | -48.90% |
| Normalized Diluted EPS | 37.04% | 2.61% | 74.02% | -10.00% | -49.75% |
| Average Basic Shares Outstanding | 0.80% | 0.70% | 0.45% | 0.46% | 33.20% |
| Average Diluted Shares Outstanding | 0.80% | 0.70% | 0.45% | 0.46% | 33.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |